Logo image of AIKI

AIKIDO PHARMA INC (AIKI) Stock Fundamental Analysis

USA - NASDAQ:AIKI - US0088753043 - Common Stock

3.56 USD
+0.01 (+0.28%)
Last: 12/21/2022, 8:17:10 PM
Fundamental Rating

3

Overall AIKI gets a fundamental rating of 3 out of 10. We evaluated AIKI against 531 industry peers in the Biotechnology industry. AIKI has a great financial health rating, but its profitability evaluates not so good. AIKI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AIKI had negative earnings in the past year.
AIKI had a negative operating cash flow in the past year.
AIKI Yearly Net Income VS EBIT VS OCF VS FCFAIKI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for AIKI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIKI Yearly ROA, ROE, ROICAIKI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -200 -400

1.3 Margins

AIKI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIKI Yearly Profit, Operating, Gross MarginsAIKI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -50K -100K -150K

More info and screens

8

2. Health

2.1 Basic Checks

AIKI has less shares outstanding than it did 1 year ago.
AIKI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AIKI Yearly Shares OutstandingAIKI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
AIKI Yearly Total Debt VS Total AssetsAIKI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 1.78, we must say that AIKI is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.78, AIKI is doing good in the industry, outperforming 65.88% of the companies in the same industry.
AIKI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACCN/A
AIKI Yearly LT Debt VS Equity VS FCFAIKI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 29.54 indicates that AIKI has no problem at all paying its short term obligations.
With an excellent Current ratio value of 29.54, AIKI belongs to the best of the industry, outperforming 96.24% of the companies in the same industry.
A Quick Ratio of 29.54 indicates that AIKI has no problem at all paying its short term obligations.
AIKI's Quick ratio of 29.54 is amongst the best of the industry. AIKI outperforms 96.24% of its industry peers.
Industry RankSector Rank
Current Ratio 29.54
Quick Ratio 29.54
AIKI Yearly Current Assets VS Current LiabilitesAIKI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AIKI have decreased strongly by -879.05% in the last year.
EPS 1Y (TTM)-879.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12993.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AIKI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-245.59%
EPS Next 2Y-5.02%
EPS Next 3Y23.38%
EPS Next 5Y11.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AIKI Yearly Revenue VS EstimatesAIKI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2024 2025 2026 5M 10M 15M 20M
AIKI Yearly EPS VS EstimatesAIKI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIKI. In the last year negative earnings were reported.
Also next year AIKI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIKI Price Earnings VS Forward Price EarningsAIKI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIKI Per share dataAIKI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as AIKI's earnings are expected to grow with 23.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.02%
EPS Next 3Y23.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AIKI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIKIDO PHARMA INC

NASDAQ:AIKI (12/21/2022, 8:17:10 PM)

3.56

+0.01 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)03-27 2023-03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.14%
Ins Owner Change0%
Market Cap19.53M
Revenue(TTM)N/A
Net Income(TTM)-16.66M
Analysts82.86
Price Target16.32 (358.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-59.55%
Min EPS beat(2)-70.13%
Max EPS beat(2)-48.97%
EPS beat(4)0
Avg EPS beat(4)-77.81%
Min EPS beat(4)-96.08%
Max EPS beat(4)-48.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-55.56%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-17.5%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-3.37
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-1.97
OCFYN/A
SpS0
BVpS14.92
TBVpS15.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.54
Quick Ratio 29.54
Altman-Z 1.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-879.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12993.62%
EPS Next Y-245.59%
EPS Next 2Y-5.02%
EPS Next 3Y23.38%
EPS Next 5Y11.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-67.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-92.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.75%
OCF growth 3YN/A
OCF growth 5YN/A

AIKIDO PHARMA INC / AIKI FAQ

What is the fundamental rating for AIKI stock?

ChartMill assigns a fundamental rating of 3 / 10 to AIKI.


What is the valuation status of AIKIDO PHARMA INC (AIKI) stock?

ChartMill assigns a valuation rating of 3 / 10 to AIKIDO PHARMA INC (AIKI). This can be considered as Overvalued.


Can you provide the profitability details for AIKIDO PHARMA INC?

AIKIDO PHARMA INC (AIKI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AIKI stock?

The Earnings per Share (EPS) of AIKIDO PHARMA INC (AIKI) is expected to decline by -245.59% in the next year.